Why Madrigal Pharmaceuticals, Inc. (MDGL) Stock Fell 5.2% on Jul 31, 2026
What happened
Madrigal Pharmaceuticals reported Q2 earnings on July 30, beating the adjusted loss estimate ($1.99 vs. $2.66 expected) with $364.25M revenue, yet shares fell 6.26% intraday as investors focused on valuation concerns and elevated commercial spending for Rezdiffra (web_catalyst). The sell-off was compounded by insider selling of ~$3.88M over the prior 90 days and a Bank of America price target reduction. Volume is elevated at 2.04x the 300-minute historical average, signaling heightened institutional activity.
Confirm August 4 earnings call details and monitor analyst consensus revisions in response to Q2 results; track Rezdiffra uptake and gross margin trends as key drivers of near-term sentiment.
Frequently asked questions
Why did Madrigal Pharmaceuticals, Inc. (MDGL) stock fall on Jul 31, 2026?
Madrigal Pharmaceuticals reported Q2 earnings on July 30, beating the adjusted loss estimate ($1.99 vs. $2.66 expected) with $364.25M revenue, yet shares fell 6.26% intraday as investors focused on valuation concerns and elevated commercial spending for Rezdiffra (web_catalyst). The sell-off was compounded by insider selling of ~$3.88M over the prior 90 days and a Bank of America price target reduction. Volume is elevated at 2.04x the 300-minute historical average, signaling heightened institutional activity.
How much did MDGL stock fall on Jul 31, 2026?
MDGL fell 5.2% during the Jul 31, 2026 trading session.